Clinical Trials Logo

Neoplasm, Residual clinical trials

View clinical trials related to Neoplasm, Residual.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 3

NCT ID: NCT03703427 Not yet recruiting - Clinical trials for Pathologic Residual Cancer Cells

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Start date: November 2018
Phase: Phase 2
Study type: Interventional

This study is designed to investigate the efficacy and safety of capecitabine versus vinorelbine as a postoperative adjuvant chemotherapy, for high risk breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.

NCT ID: NCT03684863 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Start date: October 2018
Phase: Phase 2
Study type: Interventional

This study is designed to investigate the efficacy and safety of capecitabine, as a postoperative adjuvant chemotherapy, for HER-2 positive breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.

NCT ID: NCT03249636 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia

New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia

Start date: December 2017
Phase: N/A
Study type: Observational [Patient Registry]

Acute lymphoblastic leukemia , also known as acute lymphocytic leukemia, characterized by the overproduction and accumulation of cancerous, immature white blood cells, known as lymphoblasts, causing damage and death by inhibiting the production of normal cells (such as red and white blood cells and platelets) in the bone marrow and by spreading (infiltrating) to other organs. Acute lymphoblastic leukemia is most common in childhood, with a peak incidence at 2-5 years of age and another peak in old age.

NCT ID: NCT01665001 Not yet recruiting - Clinical trials for Precursor Lymphoid Neoplasms

Personalized Therapy of Precursor Lymphoid Neoplasms

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The primary goal of this study by The Polish Adult Leukemia Group (PALG) is to verify if individual therapeutic approach taking into account biological and phenotypic differences as well as response at the level of minimal residual disease is associated with improved outcome of adults with precursor lymphoid neoplasms